ArticleApplied biochemistry and biotechnology2026
Berbamine Attenuates Chronic Kidney Disease-Associated Pruritus by Targeting MRGPRX1/MrgprC11 Signaling.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease-associated pruritus (CKD-aP) seriously affects the quality of life and currently has no satisfactory treatment. Mas-related G protein-coupled receptor X1 (MRGPRX1) in humans, corresponding to MrgprC11 in rodents, is an itch receptor. Berbamine is an alkaloid that has the effect of relieving pruritus. This study aimed to investigate the role of MRGPRX1/MrgprC11 in CKD-aP and the potential therapeutic effects of berbamine. MrgprC11 knockout (KO-MrgprC11) mice and MRGPRX1 knockout (KO-MRGPRX1) human dorsal root ganglion (DRG) cells were constructed using the CRISPR/Cas9 technology. Mice were fed adenine and injected with calcium phosphate (CaP) to establish the CKD-aP model and were injected with berbamine. DRG cells were exposed to CaP and treated with berbamine. The results showed that MrgprC11 was associated with itch, kidney injury, and inflammation in mice with CKD-aP. Berbamine attenuated itch and kidney injury. Knockout of MrgprC11 further enhanced the role of berbamine, while activation of MrgprC11 using BAM8-22 reversed the role of berbamine. The in vitro experiments showed that MRGPRX1 was related to the sensitivity to CaP and inflammatory response in CaP-induced DRG cells. Berbamine inhibited these cellular behaviors, while knockout of MRGPRX1 further enhanced the role of berbamine in vitro. In conclusion, MRGPRX1/MrgprC11 signaling plays a critical role in CKD-aP by affecting the activation of DRG cells. Berbamine ameliorates CKD-aP by targeting the MRGPRX1/MrgprC11 signaling. These findings provide promising drugs and targets for the treatment of CKD-aP.
Indexed as
Identifiers
41452414What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.